Merck
CN
  • Lamotrigine use in patients with binge eating and purging, significant affect dysregulation, and poor impulse control.

Lamotrigine use in patients with binge eating and purging, significant affect dysregulation, and poor impulse control.

The International journal of eating disorders (2013-12-18)
Mary Ellen Trunko, Terry A Schwartz, Enrica Marzola, Angela S Klein, Walter H Kaye
摘要

Some patients with symptoms of binge eating and purging are successfully treated with specific serotonin reuptake inhibitors (SSRIs), but others experience only partial or no benefit. Significant affect dysregulation and poor impulse control may be characteristics that limit responsiveness. We report on the treatment of five patients with bulimia nervosa (BN), anorexia nervosa-binge/purge type (AN-B/P) or eating disorder not otherwise specified (EDNOS), using the anticonvulsant lamotrigine after inadequate response to SSRIs. Following addition of lamotrigine to an antidepressant in four cases, and switch from an antidepressant to lamotrigine in one case, patients experienced substantial improvement in mood reactivity and instability, impulsive drives and behaviors, and eating-disordered symptoms. These findings raise the possibility that lamotrigine, either as monotherapy or as an augmenting agent to antidepressants, may be useful in patients who binge eat and purge, and have significant affect dysregulation with poor impulse control.

材料
货号
品牌
产品描述

Supelco
拉莫三嗪, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
拉莫三嗪, ≥98%, powder
Supelco
Lamotrigine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
USP
拉莫三嗪, United States Pharmacopeia (USP) Reference Standard
拉莫三嗪, European Pharmacopoeia (EP) Reference Standard
拉莫三嗪, European Pharmacopoeia (EP) Reference Standard
峰鉴别用拉莫三嗪, European Pharmacopoeia (EP) Reference Standard